Stock RAPTOR PHARMACEUTICAL CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Raptor Pharmaceutical Corp Share Price

Equities

US75382F1066

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Raptor Pharmaceutical Corp
2016 Exclusive: Drugmaker Depomed prepares to explore a sale - sources RE

Latest news about Raptor Pharmaceutical Corp

Exclusive: Drugmaker Depomed prepares to explore a sale - sources RE
More news

Press releases Raptor Pharmaceutical Corp

Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information BU
Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders PR
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information BU
RAPTOR PHARMACEUTICAL CORP. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Horizon Pharma plc BU
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients GL
More press releases

News in other languages on Raptor Pharmaceutical Corp

Depomed : Le laboratoire Depomed résigné à se vendre-sources
Apple : Les valeurs à suivre sur les marchés aùéricains
Raptor Pharmaceutical Corp. : Raptor Pharmaceutical termine le recrutement de la phase 2/3 de l’essai clinique du RP103 pour le traitement potentiel de la maladie de Huntington
Raptor Pharmaceutical Corp. : Raptor Pharmaceutical annonce la publication des résultats de phase III dans le Clinical Journal of the American Society of Nephrology
Rapr Phar : Raptor Pharmaceutical tiendra, le mardi 26 juillet 2011 à midi heure de l’Est des États-Unis, une conférence téléphonique et une webdiffusion pour discuter des résultats des essais cliniques de Phase 3
More news

Managers and Directors - Raptor Pharmaceutical Corp

Managers TitleAgeSince
Paul Hoelscher DFI
 Director of Finance/CFO 59 25/16/25
Kim Lee IRC
 Investor Relations Contact - 23/14/23
Françoise de Craecker PRN
 Corporate Officer/Principal 62 -
Members of the board TitleAgeSince
Gregg Lapointe CHM
 Chairman 65 01/15/01
Timothy Walbert BRD
 Director/Board Member 57 11/11/11
Paul Hoelscher DFI
 Director of Finance/CFO 59 25/16/25
More insiders

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+3.78% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-9.05% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock